A biological response modifier is a substance that can potentiate the innate immune response and/or improve the body’s adaptive response to infection and disease. anu bio-pharma’s proprietary technology is a disease modifying, oral administered, Rx biologic response modifier.
This pharmacological innovation
modulates the host principal to the disease.
anu bio-pharma’s first in class technology fortifies the structure and functional persistence of the epithelium and endothelium. The epithelial cells (line body cavities/organs) and endothelial cells (line blood vessels and lymphatic vessels) are essentially the body’s full time gatekeepers and first responders. Fortifying epithelial and endothelial structures enhances the function(s) of these responsive cells to limit bacterial/viral pathogens, inflammation and disease progression.
This biologic response modifier is applicable to respiratory, gastrointestinal and urothelial barrier integrity. Additionally, this technology has immuno-oncology (as an immuno-adjuvant) and cardiovascular relevance.
anu bio-pharma’s technology is regulated via the FDA’s CBER jurisdiction.
In substance, the information on this landing page provides an overview of the scope of anu bio-pharma’s innovative technology.
With respect to the licensing and commercialization of this next generation medicine, proof of concept, detailed mechanisms of action, intellectual property protection, and clinical development information
is provided via private communications.
anu is pronounced onn-you
